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Background
Eosinophilic esophagitis (EoE) is a burgeoning health
concern impacting a growing proportion of the popula-
tion. Experts advise utilization of either dietary modifi-
cations, swallowing of topical steroids or a combination
for management. We present a child with EoE refractory
to diet and topical corticosteroids who improved with
oral azathioprine (AZA).
Methods
We have a case of a 6 year old boy diagnosed with EOE
after presenting with dysphagia to solids more so than
liquids associated with severe odynophagia and vomiting.
While on a PPI, the esophageal biopsy results revealed
micro-abscesses, a thickened squamous basal layer and
>150 Eos/hpf with normal esophageal pH monitoring.
There was no evidence of increased eosinophils in the
gastric and duodenal biopsies and no peripheral blood
eosinphilia. Skin prick testing was negative to a panel of
70 foods including cow’s milk. Food patch testing
revealed no evidence of delayed hypersensitivity. He
failed to respond to several months swallowed topical
fluticasone propionate or swallowed topical budesonide.
A trial of ciclesonide swallowed was initiated but his
clinical symptoms persisted. Due to his prior failure with
swallowed topical corticosteroids, prednisone 5mg every
other day was started in addition to budesonide 1mg
inhalation suspension. During follow-up one month later,
he had worsening symptoms consisting of increased
vomiting, dysphagia with soft foods and generalized
abdominal pain. The prednisone dose was discontinued
and he was started on AZA.
Results
Follow-up four months later revealed significant
improvement in his clinical symptoms. He had no symp-
toms of solid food dysphagia, odynophagia, impaction,
abdominal pain or vomiting. His follow-up EGD still
demonstrated hyperplastic basal cell layer but a tenfold
reduction in intraepithelial eosinophils with a peak count
of 15 Eos/hpf in his esophagus and no other histologic
findings consistent with EoE. 18 months after starting
AZA, his peak esophageal biopsy intraepithelial count
remained at 15 Eos/hpf and his duodenum and stomach
remained normal. To date he continues to tolerate AZA
and has not manifested any drug adverse side effects. His
growth has actually improved while on AZA.
Conclusions
AZA has previously been used as monotherapy to induce
long term remission in adults with refractory corticoster-
oid-dependent EoE. Current review of the literature
yielded no prior reports of safely using AZA in the pedia-
tric EoE population to successfully reduce clinical symp-
toms and tissue eosinophilia as observed in our case. This
index case report suggests that AZA can be considered as
a safe adjuvant therapy in recalcitrant pediatric EoE cases.
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